secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001140361-24-045370
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q3 revenue $134M (-7% YoY); reaffirms 2024 P&L guidance; increases cash guidance to $2.2B
--------------------------------------------------------------------------------

- Q3 total revenue $134M vs $144M YoY; commercial revenue $76M, R&D revenue $58M.
- WAINUA royalty revenue $5M in Q3 ($10M YTD); SPINRAZA royalties $57M in Q3 ($152M YTD).
- Olezarsen PDUFA Dec 19, 2024 for FCS; donidalorsen PDUFA Aug 21, 2025 for HAE.
- Cash & investments $2.5B at Sep 30; raised ~$500M from 11.5M-share offering at $43.50.
- Phase 3 ION582 for Angelman syndrome to begin H1 2025 after positive FDA end-of-Phase 2 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124045370/0001140361-24-045370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124045370/ef20038192_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-045370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer